Diagnostic tool for screening the impact of product ingredients for urogenital microbiomes therapies

A testing system for urogenital products, comprising:

• a quantitative polymerase chain reaction analyzer configured to receive a female vaginal test sample with demographic information, to determine and identify DNA identification and quantification information of Lactobacillus bacteria populations in the female test sample and to determine baseline populations of the Lactobacillus bacteria populations;
• a treatment compound configured to be exposed to the Lactobacillus bacteria populations;
• a microbiome assay network platform coupled to the quantitative polymerase chain reaction analyzer configured to receive the DNA identification and the quantification information and the baseline populations and further configured to track growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations based on the exposure of the Lactobacillus bacteria to the treatment compound;
• a processor coupled to the microbiome assay network platform configured to analyze the growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations and to rank each growth inhibition pattern for at least one of a beneficial or harmful microorganism based the DNA identification and the demographic information;
• and
• a mobile application coupled to the microbiome assay network platform configured to compare the analyzed and the ranked growth inhibition patterns for the treatment compound and provide an effectiveness rank of the treatment compound.

A testing system for urogenital products, comprising:

• a quantitative polymerase chain reaction analyzer configured to receive a female vaginal test sample with demographic information, to determine and identify DNA identification and quantification information of Lactobacillus bacteria populations in the female test sample and to determine baseline populations of the Lactobacillus bacteria populations;
• a liquid chromatography device coupled to the quantitative polymerase chain reaction analyzer configured to measure and record a lactic acid concentration in the female test sample;
• a pH measuring apparatus coupled to the quantitative polymerase chain reaction analyzer configured to measure and record a pH level in the female test sample;
• a treatment compound configured to be exposed to the Lactobacillus bacteria populations;
• a microbiome assay network platform coupled to the quantitative polymerase chain reaction analyzer configured to receive the DNA identification and the quantification information, the lactic acid concentration, the pH level and the baseline populations and further configured to track growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations based on the exposure of the Lactobacillus bacteria to the treatment compound;
• a processor coupled to the microbiome assay network platform configured to analyze the growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations and to rank each growth inhibition pattern for at least one of a beneficial or harmful microorganism based the DNA identification;
• and
• a mobile application coupled to the microbiome assay network platform configured to compare the analyzed and the ranked growth inhibition patterns for the treatment compound and provide an effectiveness rank of the treatment compound.

A testing system for urogenital products, comprising:

• a quantitative polymerase chain reaction analyzer configured to receive a female vaginal test sample with demographic information, to determine and identify DNA identification and quantification information of Lactobacillus bacteria populations in the female test sample and to determine baseline populations of the Lactobacillus bacteria populations;
• a liquid chromatography device coupled to the quantitative polymerase chain reaction analyzer configured to measure and record a lactic acid concentration in the female test sample;
• a pH measuring apparatus coupled to the quantitative polymerase chain reaction analyzer configured to measure and record a pH level in the female test sample;
• a plurality of treatment compounds, wherein each treatment compound is configured to be exposed individually to the Lactobacillus bacteria populations;
• a microbiome assay network platform coupled to the quantitative polymerase chain reaction analyzer configured to receive the DNA identification and the quantification information, the lactic acid concentration, the pH level and the baseline populations and further configured to track growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations based on the exposure of the Lactobacillus bacteria by each treatment compound;
• a processor coupled to the microbiome assay network platform configured to analyze the growth inhibition patterns of the Lactobacillus bacteria populations from the baseline populations based on the exposure of the Lactobacillus bacteria by each treatment compound and to rank each growth inhibition pattern for at least one of a beneficial or harmful microorganism based the DNA identification based on the exposure of the Lactobacillus bacteria by each treatment compound;
• and
• a mobile application coupled to the microbiome assay network platform configured to compare the analyzed and the ranked growth inhibition patterns for each treatment compound and provide an effectiveness rank of each treatment compound.